Abstract
Psoriatic arthritis remains a common cause of morbidity in patients with psoriasis. Little is known about the natural history of the disease and dermatologists do not consistently screen for its presence. We describe a patient with severe psoriasis where long-term biologic therapy with a tumour necrosis factor inhibitor was interrupted for clinical reasons, leading to a rapidly evolving axial spondyloarthritis and oligoarthritis. This unusual presentation of psoriatic arthritis may reflect masking of the disease by long-term treatment with a tumour necrosis factor inhibitor. We advocate the use of screening for psoriatic arthritis, including before and during treatment with biologic therapies. © 2014 Informa Healthcare USA on behalf of Informa UK Ltd.
Original language | English |
---|---|
Pages (from-to) | 61-62 |
Number of pages | 1 |
Journal | Journal of Dermatological Treatment |
Volume | 25 |
Issue number | 1 |
DOIs | |
Publication status | Published - 2012 |
Keywords
- Biologic therapy
- Psoriasis
- Psoriatic arthritis
- Tumour necrosis factor inhibitor
- Ustekinumab